المؤلفون: Fanny Rialland, Audrey Grain, Myriam Labopin, Gerard Michel, Virginie Gandemer, Catherine Paillard, Cécile Pochon, Laurence Clement, Eolia Brissot, Charlotte Jubert, Anne Sirvent, Pierre Simon Rohrlich, Dominique Plantaz, Jean-Hugues Dalle, Mohamad Mohty

المساهمون: Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU), CHU Pontchaillou [Rennes], Université de Rennes (UR), CHU Strasbourg, Hôpital Brabois, CHU Bordeaux [Bordeaux], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Grenoble, Hôpital Robert Debré, This trial was supported by the French national cancer institute (INCa) through a grant as part of the 'Programme Hospitalier de Recherche Clinique' (PHRC-Cancer)

المصدر: Bone Marrow Transplantation
Bone Marrow Transplantation, 2022, 57 (11), pp.1698-1703. ⟨10.1038/s41409-022-01769-5⟩

مصطلحات موضوعية: MESH: Adolescent, Transplantation, MESH: Humans, Transplantation Conditioning, Adolescent, MESH: Busulfan, [SDV]Life Sciences [q-bio], MESH: Child, Preschool, Hematopoietic Stem Cell Transplantation, Hematology, MESH: Prospective Studies, Young Adult, MESH: Young Adult, MESH: Child, Child, Preschool, MESH: Vidarabine, Humans, Prospective Studies, Child, Busulfan, MESH: Hematopoietic Stem Cell Transplantation, Vidarabine, MESH: Transplantation Conditioning

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8303f5d4668f5e5b72eb083cf3649c52Test
https://doi.org/10.1038/s41409-022-01769-5Test

المؤلفون: Giebel, Sebastian, Labopin, Myriam, Sobczyk-Kruszelnicka, Malgorzata, Stelljes, Matthias, Byrne, Jenny, Fegueux, Nathalie, Beelen, Dietrich, Rovira, Montserrat, Spyridonidis, Alexandros, Blaise, Didier, Bornhäuser, Martin, Karadogan, Ihsan, Savani, Bipin, Nagler, Arnon, Mohty, Mohamad, Martin, Sonja, Chevallier, Patrice, Neubauer, Andreas, Damaj, Gandhi, Koc, Yener, Ganser, Arnold, Collin, Matthew, Yakoub-Agha, Ibrahim, Ozdogu, Hakan, Araujo, Mercedes Colorado, Itäla-Remes, Maija, Orchard, Kim, Isaksson, Cecilia, Bethge, Wolfgang, Martin, Hans, Aljurf, Mahmoud, Faber, Edgar, Caballero, Dolores, Zák, Pavel, Leleu, Xavier, Bay, Jacques-Olivier, Rohrlich, Pierre-Simon, Kröger, Nicolaus, Huynh, Anne, Schäfer-Eckart, Kerstin, Milpied, Noel, Lenhoff, Stig, Ho, Aloysius, López, Jose Luis Bello, Mordini, Nicola, Lioure, Bruno, Halaburda, Kazimierz, Olivieri, Attilio, Gedde-Dahl, Tobias, Protheroe, Rachel, Tischer, Johanna, Klammer, Matthias, Clausen, Johannes, Potter, Victoria, Ladetto, Marco, Tilly, Herve, Deconinck, Eric, Brecht, Arne, Müller, Lutz Peter, Heinicke, Thomas, Carrete, Juan Pio Torres, Bazarbachi, Ali, Reményi, Péter, Rubio, Marie Thérèse, Fanin, Renato, Pérez-Simón, Jose Antonio, Niels, Murawski, Diez-Martin, J., Arat, Mutlu, Hermine, Olivier, Socié, Gerard, Cornelissen, Jan, Santarone, Stella, Guyotat, Denis, Bulabois, Claude Eric, Bernasconi, Paolo, Johansson, Jan-Erik, Vrhovac, Radovan, Greinix, Hildegard, Lorenzo, José Luis López, Apte, Shashikant, Craddock, Charles, Kobbe, Guido, Zahrani, Mohsen Al, Dreger, Peter, Lange, Andrzej, Tbakhi, Abdelghani, Meijer, Ellen, Llamas, Carlos Vallejo, Santasusana, Josep Maria Ribera, Corradini, Paolo, Benedetti, Fabio, Rambaldi, Alessandro, Gandemer, Virginie, Malfuson, Jean-Valère, Kaare, Ain, Risitano, Antonio, Petrini, Mario, Selleri, Carmine, Wu, Depei

المساهمون: Hematology, CCA - Cancer Treatment and quality of life, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

المصدر: Bone Marrow Transplantation, 56(2), 481-491. Nature Publishing Group
Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, J L, Fegueux, N, Beelen, D W, Rovira, M, Spyridonidis, A, Blaise, D, Bornhäuser, M, Karadogan, I, Savani, B N, Nagler, A, Mohty, M & Principal investigators of the contributing institutions 2021, ' Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT ', Bone Marrow Transplantation, vol. 56, no. 2, pp. 481-491 . https://doi.org/10.1038/s41409-020-01050-7Test
Bone Marrow Transplantation
Bone Marrow Transplantation, 2021, 56 (2), pp.481-491. ⟨10.1038/s41409-020-01050-7⟩

مصطلحات موضوعية: medicine.medical_specialty, Transplantation Conditioning, MESH: Busulfan, Medizin, MESH: Graft vs Host Disease, Graft vs Host Disease, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Busulfan, MESH: Hematopoietic Stem Cell Transplantation, MESH: Transplantation Conditioning, Retrospective Studies, Transplantation, Acute leukemia, MESH: Humans, MESH: Middle Aged, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, MESH: Retrospective Studies, Retrospective cohort study, Hematology, Middle Aged, Total body irradiation, Fludarabine, Leukemia, Myeloid, Acute, Regimen, 030220 oncology & carcinogenesis, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: Leukemia, Myeloid, Acute, business, MESH: Whole-Body Irradiation, Vidarabine, Whole-Body Irradiation, 030215 immunology, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a271bda3480115a5c698ba5b59f0ad1Test
https://doi.org/10.1038/s41409-020-01050-7Test

المؤلفون: Houot, Mélanie, Poinsignon, Vianney, Mercier, Lionel, Valade, Cyril, Desmaris, Romain, Lemare, François, Paci, Angelo

المساهمون: Département de biologie et pathologie médicales Gustave Roussy, Institut Gustave Roussy (IGR), Département de pharmacie clinique Gustave Roussy, École des Hautes Études en Santé Publique EHESP (EHESP), EA Management des Organisations de Santé (EA MOS), École des Hautes Études en Santé Publique EHESP (EHESP)-PRES Sorbonne Paris Cité

المصدر: ISSN: 1174-5886 ; Drugs in R&D ; https://hal.science/hal-01514079Test ; Drugs in R&D, 2013, 13 (1), pp.87 - 94. ⟨10.1007/s40268-013-0003-y⟩.

مصطلحات موضوعية: Chronic Myeloid Leukemia, Storage Temperature, Glass Bottle, Busulfan, Autologous Hematopoietic Stem Cell Transplantation, MESH: Busulfan/chemistry, MESH: Busulfan/standards, MESH: Chemical Phenomena, MESH: Chemical Precipitation/drug effects, MESH: Drug Packaging/standards, MESH: Drug Stability, MESH: Injections, MESH: Pharmaceutical Solutions/chemistry, MESH: Pharmaceutical Solutions/standards, MESH: Time Factors, [CHIM.THER]Chemical Sciences/Medicinal Chemistry, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences

العلاقة: hal-01514079; https://hal.science/hal-01514079Test; https://hal.science/hal-01514079/documentTest; https://hal.science/hal-01514079/file/40268_2013_Article_3.pdfTest

الإتاحة: https://doi.org/10.1007/s40268-013-0003-yTest
https://hal.science/hal-01514079Test
https://hal.science/hal-01514079/documentTest
https://hal.science/hal-01514079/file/40268_2013_Article_3.pdfTest

المؤلفون: David I. Marks, Richard T. Maziarz, Mehdi Hamadani, Mary M. Horowitz, Vivek Roy, Kwang Woo Ahn, Wael Saber, Alison W. Loren, Rammurti T. Kamble, Eduardo Olavarria, Mark R. Litzow, Joerg Halter, Yoshihiro Inamoto, Jean-Yves Cahn, Gregory A. Hale, Bipin N. Savani, Baldeep Wirk, Jeff Szer, Matthew D. Seftel, Harry C. Schouten, Edmund K. Waller, Mitchell Sabloff, Edward A. Copelan, Luciano J. Costa, Brian J. Bolwell, Daniel J. Weisdorf, Koen van Besien, Mukta Arora, Marcos de Lima, Christopher Bredeson, Mahmoud Aljurf, Robert Peter Gale, Jorge E. Cortes, Betty K. Hamilton, Belinda R. Avalos, Celalettin Ustun, Matt Kalaycio, Xiaochun Zhu

المساهمون: TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Vanderbilt University [Nashville], University Hospital Basel [Basel], Mayo Clinic, Genetica & Celbiologie, Interne Geneeskunde, RS: GROW - School for Oncology and Reproduction

المصدر: Blood
Blood, American Society of Hematology, 2013, 122 (24), pp.3863-70. ⟨10.1182/blood-2013-07-514448⟩
Blood, 122(24), 3863-3870. The American Society of Hematology

مصطلحات موضوعية: Oncology, MESH: Remission Induction, MESH: Combined Modality Therapy, MESH: Busulfan, medicine.medical_treatment, MESH: Leukemia, Myeloid, Plenary Paper, Hematopoietic stem cell transplantation, Biochemistry, [SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunity, MESH: Unrelated Donors, 0302 clinical medicine, hemic and lymphatic diseases, MESH: Child, MESH: Treatment Outcome, MESH: Middle Aged, Myeloid leukemia, Hematology, Total body irradiation, 3. Good health, Leukemia, MESH: Antineoplastic Combined Chemotherapy Protocols, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Acute Disease, MESH: Whole-Body Irradiation, medicine.drug, medicine.medical_specialty, Cyclophosphamide, Immunology, MESH: Multivariate Analysis, 03 medical and health sciences, Internal medicine, medicine, MESH: Transplantation, Homologous, neoplasms, MESH: Hematopoietic Stem Cell Transplantation, MESH: Adolescent, MESH: Humans, business.industry, MESH: Time Factors, MESH: Child, Preschool, MESH: Cyclophosphamide, MESH: Adult, Cell Biology, medicine.disease, Confidence interval, MESH: Male, nervous system diseases, MESH: Siblings, Transplantation, MESH: Disease-Free Survival, business, MESH: Female, Busulfan, 030215 immunology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b664b898af8af4741d181d302daaf834Test
https://cris.maastrichtuniversity.nl/en/publications/01d8933f-1605-4365-abc9-4ee3eb749b71Test

المؤلفون: Romain Desmaris, François Lemare, Cyril Valade, Angelo Paci, Vianney Poinsignon, Mélanie Houot, Lionel Mercier

المساهمون: Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR), Département de pharmacie clinique [Gustave Roussy], École des Hautes Études en Santé Publique [EHESP] (EHESP), EA Management des Organisations de Santé (EA MOS), École des Hautes Études en Santé Publique [EHESP] (EHESP)-PRES Sorbonne Paris Cité

المصدر: Drugs in R&D
Drugs in R&D, Springer Verlag, 2013, 13 (1), pp.87-94. ⟨10.1007/s40268-013-0003-y⟩

مصطلحات موضوعية: Time Factors, Chemical Phenomena, medicine.medical_treatment, Pharmacology toxicology, Hematopoietic stem cell transplantation, [CHIM.THER]Chemical Sciences/Medicinal Chemistry, Pharmacology, Shelf life, 030226 pharmacology & pharmacy, Conditioning regimen, Injections, 03 medical and health sciences, 0302 clinical medicine, Drug Stability, MESH: Drug Stability, MESH: Chemical Precipitation/drug effects, MESH: Pharmaceutical Solutions/standards, medicine, Chemical Precipitation, MESH: Injections, Pharmaceutical Solutions, Original Research Article, Busulfan, Drug Packaging, Chemistry, MESH: Busulfan/standards, MESH: Time Factors, MESH: Chemical Phenomena, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 6. Clean water, MESH: Busulfan/chemistry, 030220 oncology & carcinogenesis, MESH: Drug Packaging/standards, MESH: Pharmaceutical Solutions/chemistry, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17bccf531bce20532f0ec0f8bd311f4bTest
https://hal.archives-ouvertes.fr/hal-01514079/documentTest

المؤلفون: P. Germaud, Mohamad Mohty, Patricia Lemarchand, Florent Malard, Béatrice Delasalle, Philippe Moreau, Patrice Chevallier, Thierry Guillaume, Arnaud Chambellan, Jacques Delaunay, S. Dirou

المساهمون: Service de Pneumologie, Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain]-Institut du Thorax, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Service Hématologie Clinique, Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), FM was supported by educational grants from the 'Association for Training, Education and Research in Hematology, Immunology and Transplantation' (ATERHIT). We also thank the 'Re'gion Pays de Loire', the 'Association pour la Recherche sur le Cancer', the 'Fondation de France', the 'Fondation contre la Leuce' mie', the 'Agence de Biome' decine', the 'Association Cent pour Sang la Vie', the 'Association Laurette Fuguain', the IRGHET and the 'Ligue Contre le Cancer' (Comite' s Grand-Ouest) for their generous and continuous support for our clinical and basic research work. Our group is supported by several grants from the French National Cancer Institute (PHRC, INCa to MM)., Lemarchand, Patricia, Université de Nantes (UN)-Institut du Thorax-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)

المصدر: Bone Marrow Transplantation
Bone Marrow Transplantation, Nature Publishing Group, 2014, 49 (5), pp.622-7. ⟨10.1038/bmt.2014.15⟩
Bone Marrow Transplantation, 2014, 49 (5), pp.622-7. ⟨10.1038/bmt.2014.15⟩

مصطلحات موضوعية: Lung Diseases, Male, Vital capacity, Transplantation Conditioning, MESH: Administration, Intravenous, MESH: Busulfan, MESH: Respiratory Function Tests, Gastroenterology, Pulmonary function testing, MESH: Lung Diseases, 0302 clinical medicine, MESH: Antilymphocyte Serum, hemic and lymphatic diseases, Medicine, Cumulative incidence, MESH: Transplantation Conditioning, MESH: Aged, education.field_of_study, MESH: Middle Aged, pulmonary function, Hematology, MESH: Follow-Up Studies, Middle Aged, MESH: Hematologic Diseases, Fludarabine, Respiratory Function Tests, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Vidarabine, Administration, Intravenous, Female, MESH: Immunosuppressive Agents, MESH: Stem Cell Transplantation, Immunosuppressive Agents, Vidarabine, medicine.drug, Adult, medicine.medical_specialty, MESH: Myeloablative Agonists, Population, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Lymphocyte Depletion, Article, 03 medical and health sciences, FEV1/FVC ratio, Young Adult, Internal medicine, MESH: Transplantation, Homologous, Humans, Transplantation, Homologous, education, Busulfan, [SDV.BC] Life Sciences [q-bio]/Cellular Biology, Aged, Antilymphocyte Serum, Retrospective Studies, MESH: Lymphocyte Depletion, Transplantation, MESH: Humans, business.industry, MESH: Adult, MESH: Retrospective Studies, Myeloablative Agonists, Hematologic Diseases, MESH: Male, Surgery, ATG, Regimen, business, MESH: Female, reduced-intensity conditioning, 030215 immunology, Follow-Up Studies, Stem Cell Transplantation

وصف الملف: application/unknown

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a819d6dbe29cd205b2247a7c70d3a6aTest
https://www.hal.inserm.fr/inserm-00955626/file/BMT_2014_dirou.pdfTest

المؤلفون: Soussain, Carole, Hoang-Xuan, Khê, Taillandier, Luc, Fourme, Emmanuelle, Choquet, Sylvain, Witz, Francis, Casasnovas, Olivier, Dupriez, Brigitte, Souleau, Bertrand, Taksin, Anne-Laure, Gisselbrecht, Christian, Jaccard, Arnaud, Omuro, Antonio, Sanson, Marc, Janvier, Maud, Kolb, Brigitte, Zini, Jean-Marc, Leblond, Véronique, Renseigné, Non

المساهمون: Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Réseau d'Etude des Gliomes, REG, Service de Neuro-Oncologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'hématologie-oncologie adultes, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie biologique [CHU Limoges], CHU Limoges, UPMC - Département de neurologie 2 - Mazarin, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

المصدر: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2008, 26 (15), pp.2512-8. ⟨10.1200/JCO.2007.13.5533⟩
Journal of Clinical Oncology, 2008, 26 (15), pp.2512-8. ⟨10.1200/JCO.2007.13.5533⟩

مصطلحات موضوعية: Male, Oncology, Cancer Research, MESH: Combined Modality Therapy, MESH: Busulfan, medicine.medical_treatment, Salvage therapy, Hematopoietic stem cell transplantation, MESH: Eye Neoplasms, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, MESH: Cytarabine, Prospective Studies, Etoposide, MESH: Etoposide, MESH: Aged, MESH: Middle Aged, Brain Neoplasms, MESH: Thiotepa, Cytarabine, Hematopoietic Stem Cell Transplantation, Middle Aged, Combined Modality Therapy, 3. Good health, MESH: Salvage Therapy, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, 030220 oncology & carcinogenesis, MESH: Brain Neoplasms, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Lymphoma, Large B-Cell, Diffuse, Intraocular lymphoma, Stem cell, MESH: Neoplasm Recurrence, Local, medicine.drug, Adult, medicine.medical_specialty, MESH: Survival Rate, 03 medical and health sciences, Multicenter trial, Internal medicine, medicine, Humans, Busulfan, Cyclophosphamide, MESH: Hematopoietic Stem Cell Transplantation, Aged, Salvage Therapy, Chemotherapy, MESH: Humans, business.industry, Eye Neoplasms, MESH: Cyclophosphamide, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Surgery, Lymphoma, MESH: Lymphoma, Large B-Cell, Diffuse, Methotrexate, Neoplasm Recurrence, Local, business, human activities, MESH: Female, Thiotepa, 030217 neurology & neurosurgery

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb14493de1660d432cd42d29ddcc39c5Test
https://hal.archives-ouvertes.fr/hal-00452931Test

المؤلفون: Zina Chir, Noel Milpied, Mauricette Michallet, Marc Renaud, Jean-Michel Boiron, Bernard Rio, Ibrahim Yakoub-Agha, Eric Deconinck, Quoc-Hung Le, Didier Blaise, Franck E. Nicolini, Bruno Lioure, Michel Attal, Helene Esperou, Thomas Prebet, Jean-Henri Bourhis, Mohamad Mohty, Pierre Bordigoni

المساهمون: Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie clinique, Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Agence de la biomédecine [Saint-Denis la Plaine], Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Service des maladies du sang, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux]-Groupe Hospitalier Sud, Service d'onco-hématologie, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département d'Hématologie et Oncologie Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service greffe de moelle osseuse, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], Saas, Philippe

المصدر: Experimental Hematology
Experimental Hematology, Elsevier, 2008, 36 (5), pp.535-44. ⟨10.1016/j.exphem.2008.01.017⟩
Experimental Hematology, 2008, 36 (5), pp.535-44. ⟨10.1016/j.exphem.2008.01.017⟩

مصطلحات موضوعية: Oncology, Male, MESH: Remission Induction, Cancer Research, Multivariate analysis, Transplantation Conditioning, MESH: Registries, MESH: Busulfan, medicine.medical_treatment, Graft vs Host Disease, Hematopoietic stem cell transplantation, 0302 clinical medicine, MESH: Antilymphocyte Serum, MESH: Risk Factors, Risk Factors, MESH: Child, Medicine, Registries, Child, MESH: Transplantation Conditioning, MESH: Treatment Outcome, MESH: Aged, MESH: Middle Aged, MESH: Time, Remission Induction, Hematopoietic Stem Cell Transplantation, MESH: Follow-Up Studies, Hematology, Total body irradiation, Middle Aged, MESH: Infant, MESH: Predictive Value of Tests, 3. Good health, Fludarabine, Treatment Outcome, MESH: Survival Analysis, 030220 oncology & carcinogenesis, Reduced Intensity Conditioning, Child, Preschool, Hematologic Neoplasms, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, Vidarabine, medicine.drug, Adult, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Adolescent, MESH: Graft vs Host Disease, MESH: Multivariate Analysis, Disease-Free Survival, Time, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, MESH: Transplantation, Homologous, Genetics, Humans, Transplantation, Homologous, Molecular Biology, Busulfan, MESH: Hematopoietic Stem Cell Transplantation, Aged, Antilymphocyte Serum, Retrospective Studies, MESH: Adolescent, MESH: Humans, business.industry, MESH: Child, Preschool, Infant, MESH: Adult, MESH: Retrospective Studies, Retrospective cohort study, Cell Biology, Survival Analysis, MESH: Male, Surgery, MESH: France, Transplantation, MESH: Disease-Free Survival, Multivariate Analysis, business, MESH: Female, MESH: Hematologic Neoplasms, 030215 immunology, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::007eddc9d70852611e759c0dd479d80eTest
https://pubmed.ncbi.nlm.nih.gov/18346838Test

المؤلفون: Patrice Chevalier, Reza Tabrizi, Hervé Tilly, Bruno Lioure, Eric Deconinck, Gérard Socié, Jill-Patrice Cassuto, Lionel Ades, Didier Blaise, Mauricette Michallet, Mathieu Kuentz, Michel Attal, Pierre Bordigoni, Thierry Facon, Frédéric Garban, Jean-Paul Vernant, Stéphane Vigouroux, Noel Milpied, Marc Bernard, Norbert Ifrah, Jean-Henri Bourhis, Marc Renaud, Raphaël Porcher

المساهمون: Centre Hospitalier Universitaire [Rennes], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Laboratoire d'Immunologie, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'onco-hématologie, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Saas, Philippe, Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC)

المصدر: Haematologica
Haematologica, Ferrata Storti Foundation, 2007, 92 (5), pp.627-34
Haematologica, 2007, 92 (5), pp.627-34
HAL

مصطلحات موضوعية: Male, Oncology, MESH: Remission Induction, Transplantation Conditioning, MESH: Busulfan, medicine.medical_treatment, Graft vs Host Disease, MESH: Antibodies, Monoclonal, 0302 clinical medicine, MESH: Antilymphocyte Serum, Antineoplastic Combined Chemotherapy Protocols, Melphalan, Etoposide, MESH: Etoposide, MESH: Transplantation Conditioning, MESH: Treatment Outcome, Hematology, MESH: Middle Aged, Remission Induction, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Total body irradiation, 3. Good health, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, 030220 oncology & carcinogenesis, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Graft vs Leukemia Effect, RIC allogeneic transplantation, Disease-Free Survival, 03 medical and health sciences, MESH: Melphalan, Humans, Cyclophosphamide, Aged, Antilymphocyte Serum, Retrospective Studies, MESH: Humans, MESH: Cyclophosphamide, MESH: Adult, MESH: Retrospective Studies, Survival Analysis, Regimen, MESH: Disease-Free Survival, MESH: Female, Busulfan, MESH: Combined Modality Therapy, T-Lymphocytes, MESH: Carmustine, Kaplan-Meier Estimate, MESH: Proportional Hazards Models, MESH: Lymphoma, Non-Hodgkin, hemic and lymphatic diseases, MESH: Cytarabine, MESH: Data Collection, MESH: Kaplan-Meiers Estimate, MESH: Aged, Data Collection, Lymphoma, Non-Hodgkin, Cytarabine, Middle Aged, Combined Modality Therapy, Fludarabine, MESH: Salvage Therapy, Treatment Outcome, medicine.anatomical_structure, MESH: Survival Analysis, MESH: Vidarabine, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, MESH: Whole-Body Irradiation, Vidarabine, Whole-Body Irradiation, medicine.drug, Adult, MESH: Survival Rate, MESH: Graft vs Host Disease, Internal medicine, medicine, MESH: Transplantation, Homologous, Transplantation, Homologous, MESH: Hematopoietic Stem Cell Transplantation, Proportional Hazards Models, Salvage Therapy, Chemotherapy, business.industry, MESH: Graft vs Leukemia Effect, Carmustine, low-grade lymphoma, MESH: Male, Surgery, Transplantation, MESH: France, MESH: T-Lymphocytes, Bone marrow, business, 030215 immunology

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f71a790778690350e9b7db0e36e46f8Test
https://www.hal.inserm.fr/inserm-00507510/file/627.pdfTest

المؤلفون: Micheline Re, Jérôme Bouligand, Estelle Daudigeos, Alain Deroussent, Paule Opolon, Gilles Vassal, Jackie Morizet, Nicolas Simonnard, Elisabeth Connault, Angelo Paci

المساهمون: Vectorologie et transfert de gènes (VTG / UMR8121), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Interactions moléculaires et cancer (IMC (UMR 8126)), Signalisation, noyaux et innovations en cancérologie (UMR8126), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Groupe d'étude de l'atmosphère météorologique (CNRM-GAME), Institut national des sciences de l'Univers (INSU - CNRS)-Météo France-Centre National de la Recherche Scientifique (CNRS), Centre national de recherches météorologiques (CNRM), Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire Midi-Pyrénées (OMP), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National d'Études Spatiales [Toulouse] (CNES)-Centre National de la Recherche Scientifique (CNRS)-Université Fédérale Toulouse Midi-Pyrénées-Météo-France -Centre National de la Recherche Scientifique (CNRS)

المصدر: Drug Metabolism and Disposition
Drug Metabolism and Disposition, American Society for Pharmacology and Experimental Therapeutics (ASPET), 2007, 35 (2), pp.306-14. ⟨10.1124/dmd.106.012880⟩

مصطلحات موضوعية: Male, MESH: Hepatic Veno-Occlusive Disease, Metabolic Clearance Rate, MESH: Busulfan, MESH: Drug Interactions, Hepatic Veno-Occlusive Disease, Pharmaceutical Science, Pharmacology, 03 medical and health sciences, chemistry.chemical_compound, Mice, 0302 clinical medicine, Pharmacokinetics, In vivo, MESH: Mice, Inbred C57BL, medicine, Animals, Drug Interactions, MESH: Animals, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], MESH: Bone Marrow Transplantation, Busulfan, MESH: Mice, 030304 developmental biology, Bone Marrow Transplantation, Glutathione Transferase, MESH: Glutathione, MESH: Metabolic Clearance Rate, 0303 health sciences, MESH: Glutathione Transferase, Glutathione, Drug interaction, Acute toxicity, MESH: Male, 3. Good health, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], Mice, Inbred C57BL, chemistry, Liver, 030220 oncology & carcinogenesis, Pharmacodynamics, Toxicity, medicine.drug, MESH: Liver

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ceae9b3fb7928b584c11b3fe718bf8bTest
https://hal.archives-ouvertes.fr/hal-00158213Test